Your browser doesn't support javascript.
loading
Sodium hyaluronate 0.30% ocular gel versus sodium hyaluronate 0.18% eye drop in the treatment of moderate to severe dry eye disease.
Calonge, Margarita; Sahyoun, Marwan; Baillif, Stéphanie; Gain, Philippe; Paw, Ewa; Mearza, Ali; Cochener, Béatrice.
Affiliation
  • Calonge M; 537068IOBA (Institute of Applied Ophthalmobiology), University of Valladolid, Valladolid, Spain.
  • Sahyoun M; 203346CIBER-BBN (Biomedical Research Networking Center Bioengineering, Biomaterials and Nanomedicine), Carlos III National Institute of Health, Spain.
  • Baillif S; Horus Pharma, Saint-Laurent-du-Var, France.
  • Gain P; Pasteur 2 University Hospital, 37045Côte d'Azur University, Nice, France.
  • Paw E; CHU de Saint-Etienne, Saint-Priest-en-Jarez, France.
  • Mearza A; Eurofins Dermscan Poland Sp. z o. o., Gdansk, Poland.
  • Cochener B; 8946Imperial College Healthcare NHS Trust, London, UK.
Eur J Ophthalmol ; 33(1): 188-195, 2023 Jan.
Article in En | MEDLINE | ID: mdl-35450456
ABSTRACT

PURPOSE:

Compare 0.30% sodium hyaluronate (0.30%HA) ocular gel with 0.18%HA eye drops in terms of improvement of ocular signs and symptoms, in patients with moderate to severe dry eye disease (DED).

METHODS:

This was a multicentric, randomized, investigator-masked, non-inferiority, comparative study conducted over 84 days. Three visits were scheduled, testing fluorescein corneal and conjunctival staining (Oxford and Van Bijsterveld scores), tear film break-up time (TBUT), Schirmer test, DED symptoms, 5-Item-Dry-Eye-Questionnaire (5-DEQ), patient and investigator satisfaction and frequency of instillation.

RESULTS:

At Day 35 (D35) and Day 84 (D84), both groups (n = 35 each) had a significant improvement in corneal staining (p < 0.001) with no inter-group difference. Van Bijsterveld score improved earlier (D35) for 0.30%HA suggesting a faster effect on conjunctival epithelium healing. There was no difference between the two concentrations in terms of TBUT or Schirmer improvements; however, the Schirmer test increase was only significant for 0.30%HA at D35 (p = 0.040). At D35 and D84, both groups showed similar improvements of DED symptoms and DEQ-5 score. Furthermore, treatment satisfaction was similar for the 2 formulations suggesting that daily use of 0.30%HA do not cause gel-related blurred vision disturbances. Frequency of instillation was similar for both groups.

CONCLUSION:

Our study demonstrates the non-inferiority of 0.30%HA gel compared to 0.18%HA solution in patients with moderate to severe DED. Because of its gel formulation and higher HA concentration providing prolonged comfort without causing visual disturbances, 0.30%HA gel might be adapted for bedtime use or during the day in more severe conditions.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dry Eye Syndromes / Hyaluronic Acid Type of study: Clinical_trials Limits: Humans Language: En Journal: Eur J Ophthalmol Journal subject: OFTALMOLOGIA Year: 2023 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dry Eye Syndromes / Hyaluronic Acid Type of study: Clinical_trials Limits: Humans Language: En Journal: Eur J Ophthalmol Journal subject: OFTALMOLOGIA Year: 2023 Document type: Article Affiliation country: